Analysts Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) PT at $25.67

Entrada Therapeutics, Inc. (NASDAQ:TRDA) has been assigned an average rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $25.6667.

Several research firms have recently issued reports on TRDA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entrada Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded Entrada Therapeutics to a “hold” rating in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th.

Institutional Trading of Entrada Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. State of Wyoming boosted its stake in Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after purchasing an additional 4,295 shares during the period. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics during the 2nd quarter valued at approximately $68,000. Inscription Capital LLC bought a new stake in Entrada Therapeutics during the 3rd quarter valued at approximately $69,000. IHT Wealth Management LLC bought a new stake in Entrada Therapeutics during the 2nd quarter valued at approximately $72,000. Finally, Virtus Investment Advisers LLC boosted its stake in Entrada Therapeutics by 32.1% during the 2nd quarter. Virtus Investment Advisers LLC now owns 11,979 shares of the company’s stock valued at $80,000 after purchasing an additional 2,914 shares during the period. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Stock Performance

Shares of NASDAQ TRDA opened at $6.95 on Wednesday. The stock has a market cap of $264.38 million, a price-to-earnings ratio of -3.90 and a beta of -0.11. The business has a 50 day simple moving average of $5.84 and a 200 day simple moving average of $6.76. Entrada Therapeutics has a 52 week low of $4.93 and a 52 week high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.18). The company had revenue of $1.98 million for the quarter, compared to the consensus estimate of $8.17 million. Entrada Therapeutics had a negative return on equity of 17.81% and a negative net margin of 92.30%. On average, analysts predict that Entrada Therapeutics will post 1.12 EPS for the current year.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.